Respiratory syncytial virus vaccine – Epidemiology – Epidemiology- Respiratory Syncytial Virus Vaccine- Mature Markets
Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the population recommended to receive the RSV vaccine for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s RSV vaccine forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the RSV vaccine-eligible population over the forecast period?
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate’s Epidemiology forecasts six RSV vaccine patient populations, as follows:
- Pediatric population eligible for the RSV vaccine.
- Adult population eligible for the RSV vaccine.
- Maternal population eligible for the RSV vaccine.
- Pediatric population newly eligible for the RSV vaccine.
- Adult population newly eligible for the RSV vaccine.
- Maternal population newly eligible for the RSV vaccine.
Note: Coverage may vary by country and region.
